SLNO

Soleno Therapeutics, Inc.

Fundamental data last updated:August 29, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

 


Analyze SLNO on TradingView

VALUATION

P/E

28.75

Market Cap ($M USD)

$2.76B

Forward P/E

3.70

PEG

0.01

PRICE TO SALES

9.69

PRICE TO BOOK

5.57

EV / EBITDA

25.68

5-Year Average P/E

Free Cash Flow Yield

3.82%

DCF Value

$152.98

Graham Number

$19.87

Price to FCF

26.16

EV to FCF

24.95

Earnings Yield

3.48%

FCF Yield

3.82%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.84

Next Year EPS Growth Estimate

$14.32

Next Year Revenue Growth Estimate

$1.62B

Return on Equity (ROE)

22.86%

FREE CASH FLOW

Operating Margin

30.80%

Debt-to-Equity

0.01

Piotroski F-Score

7

Altman Z-Score

15.35

Return on Invested Capital (ROIC)

15.95%

Current Ratio

5.62

Quick Ratio

5.32

Net Debt to EBITDA

-1.25

Interest Coverage

16.23

Gross Profit margin

98.63%

FCF PER SHARE

$2.03

REVENUE PER SHARE

$5.47

Analyze SLNO on TradingView

Gainseekers Quantitative Analysis

Summary

SLNO’s valuation presents a compelling opportunity for deep value investors. Recent pricing indicated it traded significantly below its DCF value, suggesting a market mispricing. With a Forward P/E of just 4.03 and an Altman Z-score of 15.33, the company appears both undervalued and financially robust. The earnings yield of 3.48% may seem modest, but the explosive EPS growth forecasted for next year could dramatically enhance returns. Overall, the financial health and growth prospects signal a strong buy for those seeking undervalued gems.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, SLNO is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with modern tech shifts, providing resilience against obsolescence. As AI continues to evolve, SLNO could capitalize on these trends to enhance its R&D efficiency.

The Bull Case

For value or GARP investors, SLNO offers a tantalizing proposition. The company boasts a robust ROIC of 15.86%, indicating efficient capital allocation and strong returns on investments. A Piotroski F-Score of 6 suggests solid financial health, while a free cash flow yield of 3.83% underscores its ability to generate cash. With an operating margin of 30.63%, SLNO demonstrates significant pricing power, making it an attractive buy for those seeking growth at a reasonable price.

The Bear Case

Despite its strengths, SLNO is not without risks. The Price/Sales ratio of 9.68 and Price/Book of 5.56 suggest the stock is priced for perfection, leaving little room for error. The earnings surprise of -17.81% raises concerns about management's ability to meet expectations. Additionally, trading near its 52-week high, the stock may be technically overextended, posing a risk of correction.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$80.00

Institutional Ownership %

1-Year Beta

-2.22

Insider Buying % (6 Mo)

Distance to 52-Week High

70.38%

Distance to 52-Week Low

44.48%

EARNINGS SURPRISE %

-19.18%

50-DAY SMA

$45.78

200-DAY SMA

$51.16

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.